eMed (@eMedHealth) header
eMed (@eMedHealth) profile picture

eMed

@eMedHealth

Employer GLP-1 care, done right. Clinically supported programs that keep employees healthy and businesses thriving.

emed.com/
Joined October 2021
  • Tweets174
  • Following239
  • Followers4.8K
74Media
Photo by eMed (@eMedHealth)Photo by eMed (@eMedHealth)Photo by eMed (@eMedHealth)Photo by eMed (@eMedHealth)Photo by eMed (@eMedHealth)Photo by eMed (@eMedHealth)Photo by eMed (@eMedHealth)
Short-term win, Much bigger, long-term bill. The cost doesn't disappear. It shows up in bigger claims, more sick days, lower productivity and turnover. Employers don't have to choose between their budget and their people. You should be rethinking not cutting. @eMedHealth
CNBC Make It (@CNBCMakeIt) profile pictureCNBC Make It
@CNBCMakeIt15h
Workers and researchers see benefits in GLP-1 access. Companies are weighing the costs cnbc.com/make-it/2026/10/29/…
Workers and researchers see benefits in GLP-1 access. Companies are weighing the costs

Workers and researchers see benefits in GLP-1 access. Companies are weighing the costs

As GLP-1 use reaches new highs, more employers are grappling with whether the benefits of covering these medications justify their high costs.

cnbc.com
3
4
55
14,277
Replying to @eMedHealth
@eMedHealth is leading the charge in healthcare transformation, and the FQ Health Summit was just the beginning. Now healthcare needs to move at the speed we deserve. @eMedHealth and the @femalequotient kicked off the Next Era of Women's Health with @SheMed_UK founders Chloe & Olivia Ferro, & @ShelleyZalis.
Image from Linda Yaccarino (@lindayaX)
Image from Linda Yaccarino (@lindayaX)
10
5
2
66
17,517
We thought GLP-1s were about the scale. Turns out they’re rewriting the history of our health! Heart, kidney, liver, joints, sleep, addiction. Once-in-a-lifetime medicines. The list is still growing. @EricTopol
Eric Topol (@EricTopol) profile pictureEric Topol
@EricTopolOct 1
The list of GLP-1 drug benefits independent of weight loss keep growing
Image from Eric Topol (@EricTopol)
42
62
7
724
107,911
Pharmacy costs are immediate and visible. The broader impact can take longer to surface. So what happens when GLP-1 programs are evaluated based on what shows up first? Our latest What People Are Asking piece looks at why timing matters when evaluating GLP-1 program performance. Click the link to read more: emed.com/resources/blog-post…
Image from eMed (@eMedHealth)
3
315
Employees are frustrated, even angry right now. Employers cutting GLP-1 coverage to save money are being short sighted. Losing access to medication people rely on isn't an option. GLP-1s are essential modern healthcare, and they reduce long-term costs too. Ask your employer about @eMedHealth. bloomberg.com/news/articles/…
GLP-1 Users Are Furious After Employers Drop Insurance Benefits

GLP-1 Users Are Furious After Employers Drop Insurance Benefits

Nearly half of large US companies covered the popular drugs last year, but that number is beginning to fall as they grapple with the medications’ high prices.

bloomberg.com
11
9
2
92
31,087
GLP-1s have changed what's possible in healthcare, and employees are counting on them. Employers should be expanding access, not cutting it. That's exactly what @eMedHealth was built for. washingtonpost.com/business/…
Why it may become harder to get coverage for GLP-1 weight-loss drugs

Why it may become harder to get coverage for GLP-1 weight-loss drugs

For those who rely on the medications, the difference between health plans that cover them and those that don't can mean hundreds of dollars a month.

washingtonpost.com
8
7
1
62
27,339
Betting on yourself. Writing your own playbook. Building @eMedHealth. That's what I got into with @LizClaman. Listen here: podcasts.apple.com/us/podcas…
Image from Linda Yaccarino (@lindayaX)
Image from Linda Yaccarino (@lindayaX)
20
17
1
296
34,535
GLP-1 care shouldn’t end when the prescription is written. What happens between visits matters: tracking progress, addressing side effects, supporting nutrition and strength, and adapting care as needs change. That’s where program design makes a difference.
1
1
3
532
90% of eMed GLP-1 Program Participants stay adherent to their program. Why it matters: population health is about identifying risk, intervening early, and keeping people engaged over time. That’s our model.
Image from eMed (@eMedHealth)
1
1
461
GLP-1 ROI is only as strong as the assumptions behind it. Here’s how to build a model your CFO can trust. emed.com/resources/blog-post…
Image from eMed (@eMedHealth)
1
319
Worth knowing: A 2025 analysis of 719,000+ employees found that work-loss costs increased with each higher obesity category. The workforce impact goes well beyond healthcare claims. pmc.ncbi.nlm.nih.gov/article…
Work loss among privately insured employees with overweight and obesity in the United States

Work loss among privately insured employees with overweight and obesity in the United States

Rising obesity rates in the workforce are accompanied by a hidden cost burden to employers due to work productivity loss. Understanding the impact of obesity on work productivity is essential for...

pmc.ncbi.nlm.nih.gov
218
The prescription is not the program. Members on eMed's program lost an average of 41.6 lbs at 12 months. That's what happens when support doesn't stop after the script gets filled. Source: eMed internal member outcomes data, 12-month GLP-1-naive cohort (N=416)
2
237
When food noise fades, healthy habits become easier to sustain. That’s what comprehensive obesity care is designed to support. Learn more: emed.com/resources/blog-post…
Why Workplace Wellness Challenges Rarely Create Lasting Habits

Why Workplace Wellness Challenges Rarely Create Lasting Habits

Many workplace wellness challenges create short-term motivation but fail to support lasting behavior change. Explore why sustainable employee health requires consistency, accountability, and long-t...

emed.com
3
213
Bank of America CEO Brian Moynihan is right to raise the question of GLP-1 costs. But here's the bigger question every employer should be asking: What's the cost of doing nothing? Chronic disease is already one of the largest costs facing employers. The medication is the catalyst, not the strategy. The organizations that come out ahead will focus on outcomes, adherence, and long-term health, not just pharmacy spend. cnbc.com/2026/08/05/bank-of-…
Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says

Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says

Employers have grappled with soaring demand for GLP-1 drugs such as Ozempic and Wegovy, which can cost thousands of dollars per patient annually.

cnbc.com
16
13
86
27,488
64% of the US workforce are obese or overweight. The total economic burden was: $425.5B in 2023 alone. ajmc.com/view/medication-use…
1
1
188
Chronic workplace stress isn't just a productivity problem. It's a metabolic one. Prolonged cortisol exposure contributes to insulin resistance, visceral fat, and systemic inflammation. The body keeps the score. Salehidoost & Korbonits, J Neuroendocrinol 2022 (PMID: 35980242)
1
197
We're curious: what actually stops people from staying on a GLP-1 program?
0%Side effects
0%No clinical oversight
40%Unsustainable program
60%Not seeing results
5 votes • Final results
2
185
During our recent eMed x @Aon_plc webinar on the future of employer-sponsored GLP-1 programs, Byron Beebe highlighted a shift in how employees experience healthcare. “Employees aren't just patients anymore, they're consumers.” Employer GLP-1 programs are increasingly judged not just on access, but on the experience they deliver.
2
175
Starting a GLP-1 program: relatively straightforward. Sustaining it with the right support structure: that's where the work is.
2
180
Load more